Moderna says new data provides 'good news for parents of children under 6'
Is Moderna's COVID-19 vaccine finally on the way for kids under six?
The company said Wednesday its coronavirus vaccine generated a strong immune response in children between six months and six years old, NBC News reports. The vaccine was given to kids at a lower dose than is given to adults.
The data comes from a trial that consisted of about 6,900 children, and Moderna said the vaccine generated a "robust neutralizing antibody response" both in kids between six months and under two years old and kids between two and six years old. The "majority of adverse events were mild or moderate," the company also said.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age," Moderna CEO Stéphane Bancel said. "We now have clinical data on the performance of our vaccine from infants six months of age through older adults. Given the need for a vaccine against COVID-19 in infants and young children we are working with the U.S. FDA and regulators globally to submit these data as soon as possible."
The vaccine was about 43.7 percent effective against the Omicron variant in children between six months and two years old and 37.5 percent effective in kids between two and five years old.
Moderna now plans to seek emergency use authorization for the vaccine in kids under six from the FDA. NBC medical correspondent John Torres said on the Today show this FDA approval will be a "huge game-changer," and he speculated it could happen within the next month or so. "That's going to let us get back to more normal lives," Torres added.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
How to financially prepare for divorceThe Explainer Facing ‘irreconcilable differences’ does not have to be financially devastating
-
Why it’s important to shop around for a mortgage and what to look forThe Explainer You can save big by comparing different mortgage offers
-
4 ways to save on rising health care costsThe Explainer Health care expenses are part of an overall increase in the cost of living for Americans
-
A fentanyl vaccine may be on the horizonUnder the radar Taking a serious jab at the opioid epidemic
-
Health: Will Kennedy dismantle U.S. immunization policy?Feature ‘America’s vaccine playbook is being rewritten by people who don’t believe in them’
-
How dangerous is the ‘K’ strain super-flu?The Explainer Surge in cases of new variant H3N2 flu in UK and around the world
-
Vaccine critic quietly named CDC’s No. 2 officialSpeed Read Dr. Ralph Abraham joins another prominent vaccine critic, HHS Secretary Robert F. Kennedy Jr.
-
This flu season could be worse than usualIn the spotlight A new subvariant is infecting several countries
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
